Human immunodeficiency virus-related lymphoma: Relation between clinical features and histologic subtypes

被引:42
作者
Gabarre, J
Raphael, M
Lepage, E
Martin, A
Oksenhendler, E
Xerri, L
Tulliez, M
Audouin, J
Costello, R
Golfier, JB
Schlaifer, D
Hequet, O
Azar, N
Katlama, C
Gisselbrecht, C
机构
[1] Hop La Pitie Salpetriere, Serv Hematol Clin, F-75013 Paris, France
[2] Hop La Pitie Salpetriere, Dept Malad Infect, F-75013 Paris, France
[3] Hop Avicenne, Serv Hematol Biol, F-93009 Bobigny, France
[4] Serv Anatomopathol, Bobigny, France
[5] Hop Henri Mondor, Unite Informat Med, F-94010 Creteil, France
[6] Hop St Louis, Serv Immunohematol, F-75475 Paris, France
[7] Inst J Paoli I Calmettes, Serv Anatomopathol, F-13009 Marseille, France
[8] Inst J Paoli I Calmettes, Inst Hematol, F-13009 Marseille, France
[9] Hop Cochin, Serv Anatomopathol, F-75674 Paris, France
[10] Hop Hotel Dieu, Serv Anatomopathol, F-75181 Paris, France
[11] Inst J Paoli I Calmettes, Dept Hematol, F-13009 Marseille, France
[12] Hop Purpan, Hematol Serv, Toulouse, France
[13] Ctr Hosp Lyon Sud, Serv Hematol, F-69310 Pierre Benite, France
关键词
D O I
10.1016/S0002-9343(01)01020-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PURPOSE: Non-Hodgkin's lymphoma occurs frequently in patients with human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS). We determined the association between the clinical and histologic features of HIV-related lymphoma. SUBJECTS AND METHODS: We reviewed the medical records of 291 patients with noncerebral HIV-related lymphoma who had been treated in multicenter trials coordinated by the Groupe d'Etude des Lymphomes de l'Adulte between 1988 and 1997. This study was performed mainly before the availability of combination antiretroviral therapy. RESULTS: The main histologic subtypes were centroblastic lymphoma in 131 patients (45%), immunoblastic lymphoma in 39 patients (13%), and Burkitt's lymphoma (including the classical form and the variant with plasmacytic differentiation) in 115 patients (40%). Burkitt's lymphoma was the most aggressive form, whereas immunoblastic lymphoma occurred in severely immunodeficient patients. Two-year survival after enrollment was 15% in immunoblastic lymphoma, 32% in Burkitt's lymphoma, and 31% in centroblastic lymphoma (P = 0.006), but multivariate analysis did not confirm the independent prognostic value of histologic subtype. Instead, five independent pretreatment factors increased the risk of mortality: age 40 years or older [relative risk (RR) = 1.5; 95% confidence interval (0): 1.1 to 2.1; P = 0.005], elevated serum lactate dehydrogenase level (RR = 1.5; 95% CI: 1.1 to 2.1; P = 0.02), having a diagnosis of AIDS before lymphoma (RR = 1.8; 95% CI: 1.2 to 2.6; P = 0.006), CD4(+) cell count less than 100 X 10(6)/L (RR = 1.8; 95% CI: 1.3 to 2.6; P = 0.0004), and impaired performance status (RR = 2.4; 95% CI: 1.7 to 3.4; P <0.0001). CONCLUSION: Several pretreatment characteristics of HIV-related lymphoma were linked to the histologic form, but HIV disease parameters other than those of lymphoma were the main determinants of outcome, so the histologic features of the lymphoma were not associated with prognosis. Am J Med. 2001;111:704-711. (C) 2001 by Excerpta Medica, Inc.
引用
收藏
页码:704 / 711
页数:8
相关论文
共 54 条
[21]   INFLUENCE OF MOLECULAR CHARACTERISTICS ON CLINICAL OUTCOME IN HUMAN IMMUNODEFICIENCY VIRUS-ASSOCIATED NON-HODGKINS-LYMPHOMA - IDENTIFICATION OF A SUBGROUP WITH FAVORABLE CLINICAL OUTCOME [J].
KAPLAN, LD ;
SHIRAMIZU, B ;
HERNDIER, B ;
HAHN, J ;
MEEKER, TC ;
NG, V ;
VOLBERDING, PA ;
MCGRATH, MS .
BLOOD, 1995, 85 (07) :1727-1735
[22]   Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection [J].
Kaplan, LD ;
Straus, DJ ;
Testa, MA ;
VonRoenn, J ;
Dezube, BJ ;
Cooley, TP ;
Herndier, B ;
Northfelt, DW ;
Huang, J ;
Tulpule, A ;
Levine, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (23) :1641-1648
[23]  
KAPLAN LD, 1989, JAMA-J AM MED ASSOC, V261, P719
[24]   CUTANEOUS PRESENTATIONS OF LYMPHOMA IN HUMAN-IMMUNODEFICIENCY-VIRUS DISEASE - PREDOMINANCE OF T-CELL LINEAGE [J].
KERSCHMANN, RL ;
BERGER, TG ;
WEISS, LM ;
HERNDIER, BG ;
ABRAHMS, KM ;
HEON, V ;
SCHULZE, K ;
KAPLAN, LD ;
RESNIK, SD ;
LEBOIT, PE .
ARCHIVES OF DERMATOLOGY, 1995, 131 (11) :1281-1288
[25]   LYMPHOID NEOPLASIA ASSOCIATED WITH THE ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) - THE NEW-YORK-UNIVERSITY-MEDICAL-CENTER EXPERIENCE WITH 105 PATIENTS (1981-1986) [J].
KNOWLES, DM ;
CHAMULAK, GA ;
SUBAR, M ;
BURKE, JS ;
DUGAN, M ;
WERNZ, J ;
SLYWOTZKY, C ;
PELICCI, PG ;
DALLAFAVERA, R ;
RAPHAEL, B .
ANNALS OF INTERNAL MEDICINE, 1988, 108 (05) :744-753
[26]   AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy - The Swiss HIV Cohort Study [J].
Ledergerber, B ;
Erard, V ;
Weber, R ;
Hirschel, B ;
Furrer, H ;
Battegay, M ;
Vernazza, P ;
Bernasconi, E ;
Opravil, M ;
Kaufmann, D ;
Sudre, P ;
Francioli, P ;
Telenti, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (23) :2220-2226
[27]  
LEVINE AM, 1991, CANCER, V68, P2466, DOI 10.1002/1097-0142(19911201)68:11<2466::AID-CNCR2820681124>3.0.CO
[28]  
2-G
[29]   LOW-DOSE CHEMOTHERAPY WITH CENTRAL-NERVOUS-SYSTEM PROPHYLAXIS AND ZIDOVUDINE MAINTENANCE IN AIDS-RELATED LYMPHOMA - A PROSPECTIVE MULTIINSTITUTIONAL TRIAL [J].
LEVINE, AM ;
WERNZ, JC ;
KAPLAN, L ;
RODMAN, N ;
COHEN, P ;
METROKA, C ;
BENNETT, JM ;
RARICK, MU ;
WALSH, C ;
KAHN, J ;
MILES, S ;
EHMANN, WC ;
FEINBERG, J ;
NATHWANI, B ;
GILL, PS ;
MITSUYASU, R .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (01) :84-88
[30]  
Levine AM, 2000, BLOOD, V96, P4084